Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tricuspid Valve Insufficiency | 6 | 2023 | 20 | 2.360 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2023 | 176 | 1.820 |
Why?
|
| Partial Thromboplastin Time | 1 | 2020 | 9 | 0.690 |
Why?
|
| Factor Xa | 1 | 2020 | 5 | 0.690 |
Why?
|
| Blood Coagulation | 1 | 2020 | 39 | 0.670 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 35 | 0.670 |
Why?
|
| Heparin | 1 | 2020 | 116 | 0.640 |
Why?
|
| Tricuspid Valve | 6 | 2023 | 25 | 0.590 |
Why?
|
| Treatment Outcome | 8 | 2023 | 5686 | 0.380 |
Why?
|
| Cardiac Catheterization | 4 | 2023 | 283 | 0.310 |
Why?
|
| Electrocardiography | 2 | 2020 | 554 | 0.270 |
Why?
|
| Severity of Illness Index | 4 | 2023 | 1553 | 0.250 |
Why?
|
| Ventricular Remodeling | 2 | 2023 | 83 | 0.240 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6660 | 0.230 |
Why?
|
| Histone Acetyltransferases | 1 | 2024 | 59 | 0.220 |
Why?
|
| RNA, Double-Stranded | 1 | 2024 | 112 | 0.210 |
Why?
|
| Interferons | 1 | 2024 | 73 | 0.210 |
Why?
|
| Heart Failure | 2 | 2023 | 917 | 0.210 |
Why?
|
| Chromatin | 2 | 2018 | 608 | 0.200 |
Why?
|
| Cytidine Deaminase | 1 | 2023 | 86 | 0.190 |
Why?
|
| Stem Cells | 1 | 2024 | 259 | 0.190 |
Why?
|
| Mice, Knockout | 2 | 2024 | 2109 | 0.180 |
Why?
|
| Humans | 17 | 2023 | 63468 | 0.180 |
Why?
|
| Data Warehousing | 1 | 2020 | 7 | 0.170 |
Why?
|
| RNA Stability | 1 | 2021 | 102 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1094 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 108 | 0.170 |
Why?
|
| Shock, Cardiogenic | 1 | 2022 | 102 | 0.170 |
Why?
|
| Troponin T | 1 | 2020 | 25 | 0.170 |
Why?
|
| Aged | 5 | 2023 | 14443 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2020 | 121 | 0.160 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2021 | 144 | 0.160 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 17 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 178 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 112 | 0.160 |
Why?
|
| Female | 10 | 2023 | 32891 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 153 | 0.150 |
Why?
|
| Heart Rate | 1 | 2020 | 322 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 216 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 51 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 297 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 46 | 0.150 |
Why?
|
| Male | 8 | 2023 | 29907 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2020 | 218 | 0.140 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2018 | 107 | 0.140 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2017 | 12 | 0.140 |
Why?
|
| Iron-Binding Proteins | 1 | 2017 | 11 | 0.140 |
Why?
|
| Friedreich Ataxia | 1 | 2017 | 7 | 0.140 |
Why?
|
| Incidence | 1 | 2022 | 1377 | 0.140 |
Why?
|
| Patient Admission | 1 | 2019 | 198 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 317 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2020 | 361 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 190 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 674 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2020 | 2081 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 66 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 360 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 564 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2024 | 3036 | 0.110 |
Why?
|
| Middle Aged | 5 | 2021 | 17609 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 834 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1101 | 0.090 |
Why?
|
| New York City | 2 | 2021 | 80 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 190 | 0.080 |
Why?
|
| Comorbidity | 2 | 2023 | 1124 | 0.070 |
Why?
|
| Prognosis | 2 | 2020 | 1748 | 0.060 |
Why?
|
| Cell Self Renewal | 1 | 2024 | 13 | 0.060 |
Why?
|
| Intestines | 1 | 2024 | 165 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 2462 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2023 | 55 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2023 | 88 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2023 | 130 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 243 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 198 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2023 | 5462 | 0.050 |
Why?
|
| Mitochondria | 1 | 2024 | 371 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 456 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 160 | 0.040 |
Why?
|
| India | 1 | 2020 | 159 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 5356 | 0.040 |
Why?
|
| Animals | 3 | 2024 | 20664 | 0.040 |
Why?
|
| Mice | 2 | 2024 | 10844 | 0.040 |
Why?
|
| PAX5 Transcription Factor | 1 | 2018 | 13 | 0.040 |
Why?
|
| Azepines | 1 | 2018 | 21 | 0.040 |
Why?
|
| Boston | 1 | 2019 | 252 | 0.040 |
Why?
|
| Acetylation | 1 | 2018 | 120 | 0.040 |
Why?
|
| Triazoles | 1 | 2018 | 56 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2019 | 146 | 0.040 |
Why?
|
| RNA Polymerase II | 1 | 2017 | 84 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1277 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 988 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 501 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 304 | 0.030 |
Why?
|
| Nicaragua | 1 | 2016 | 17 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 23 | 0.030 |
Why?
|
| Urinalysis | 1 | 2016 | 38 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2021 | 876 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1079 | 0.030 |
Why?
|
| Creatinine | 1 | 2016 | 136 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 173 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 430 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 671 | 0.030 |
Why?
|
| Histones | 1 | 2018 | 481 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 1408 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 400 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 2609 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 131 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1469 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1603 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3396 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 878 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 1361 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2338 | 0.030 |
Why?
|
| Proteins | 1 | 2018 | 750 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1256 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 1380 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 3771 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 16830 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2569 | 0.020 |
Why?
|